Taylor Swift breaks U.S. record for first-week album sales

Financial Performance - Johnson & Johnson's adjusted earnings per share of $2.80 beat expectations of $2.76 [1] - Johnson & Johnson's revenue reached $23.99 billion, surpassing the consensus of $23.8 billion [1][2] - The company is raising its full-year sales outlook, projecting $93.7 billion in revenue for 2025, exceeding the street's expectation of $93.4 billion [1][2] - Johnson & Johnson reaffirms its full-year guidance for adjusted earnings per share, estimating $10.80 to $10.90, aligning with the street's expectation of $10.86 [2] Business Strategy - Johnson & Johnson plans to separate its orthopedics business into a standalone entity named Dew Cthus [3] - The separation of the orthopedics business is expected to be completed within the next 18 to 24 months [3] - The orthopedics business accounts for approximately 9% to 10% of Johnson & Johnson's overall sales, amounting to around $9.2 billion [3] Market Reaction - Johnson & Johnson's shares are up by about 125% [4]